PERPHENAZINE FENDIZOATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H26ClN3OS.C20H14O4
Molecular Weight	722.291
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC=CC=C1C(=O)C2=CC=C(O)C(=C2)C3=CC=CC=C3.OCCN4CCN(CCCN5C6=CC=CC=C6SC7=CC=C(Cl)C=C57)CC4

InChI

InChIKey=SPGWGYWYOAUBIB-UHFFFAOYSA-N

InChI=1S/C21H26ClN3OS.C20H14O4/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26;21-18-11-10-14(12-17(18)13-6-2-1-3-7-13)19(22)15-8-4-5-9-16(15)20(23)24/h1-2,4-7,16,26H,3,8-15H2;1-12,21H,(H,23,24)

HIDE SMILES / InChI

Molecular Formula	C21H26ClN3OS
Molecular Weight	403.969
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C20H14O4
Molecular Weight	318.3228
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=39012 | http://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400315_1172004B1030_2_11

Perphenazine fendizoate is a salt of a typical antipsychotic drug perphenazine and fendizoic acid. Perhpenazien fendizoate is approved in Japan for the treatment of schizophrenia, preoperative and postoperative nausea and vomiting, and Meniere's disease (dizziness, ear ringing).

Approval Year

PubMed

Title	Date	PubMed
Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine.	2014-06	24709263
Antitubercular pharmacodynamics of phenothiazines.	2013-04	23228936
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011-07-14	21599003
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.	1998-10	9766782
Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report.	1997-12-01	9386853
Induction of mania by risperidone resistant to mood stabilizers.	1997-02	9004061
BMY-14802 reversed the sigma receptor agonist-induced neck dystonia in rats.	1996	9013402
The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery.	1995-07	7598243
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.	1994-03	7908055
Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.	1993-12	7508675
The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.	1990-08	2199431
Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study.	1987-07	3615572
Neuroleptic malignant syndrome during perphenazine treatment.	1987-03	3588517
L-tryptophan in drug-induced movement disorders with insomnia.	1986-05-08	3702925
Tourette-like syndrome following low dose short-term neuroleptic treatment.	1986-05	3459568
A case of progressive hemichorea responsive to high-dose reserpine.	1986-03	3949727
Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.	1986	2880362
GABAergic, dopaminergic and cholinergic interactions in perphenazine-induced catatonia in rats.	1985-12	3938209
Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain.	1985-04	2409454
Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes.	1984-09	6147851
Unique sensitivity of Hb Zürich to oxidative injury by phenazopyridine: reversal of the effects by elevating carboxyhemoglobin levels in vivo and in vitro.	1983-06	6859031
Cerebellar syndrome following neuroleptic induced heat stroke.	1983-02	6842224
Dose-response relationships of perphenazine in the treatment of acute psychoses.	1982	6817364
Actions of clonidine on convulsions and behaviour.	1981-07	7305545
Prolactin and the small intestine. Effect of hyperprolactinaemia on mucosal structure in the rat.	1981-07	7262630
Tricyclic antidepressants and alcoholic blackouts.	1981-06	7229637
Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.	1981	6794071
Pituitary sensitivity to LHRH in hyperprolactinemia induced by perphenazine and renal pituitary transplants in female rats.	1980-04	6770916
Electrophysiologic studies of perphenazine and protriptyline in a patient with psychotropic drug-induced ventricular fibrillation.	1979-08	463940
Seven cases of somnambulism induced by drugs.	1979-07	453369
Metoclopramide and dystonic reactions in Sardinians.	1979-06-23	87799
Toxic psychosis with cimetidine.	1979-05	434259
Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule.	1978-10-07	709472
[Acute dystonia in children. 2 cases caused by perphenazine (Trilafon)].	1978-03-10	635871
Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms.	1977-03-12	65671
Asymptomatic idiopathic syndrome of prolonged Q-T interval in a 45-year-old woman. Ventricular tachyarrhythmias precipitated by hypokalemia and therapy with amitriptyline and prephenazine.	1977-02	832494
Letter: Side-effects of perphenazine.	1975-06-21	48972
The mechanism of the potentiating effect of antidepressant drugs on the protective influenc oe of diphenhydramine in experimental catatonia. The role of histamine.	1974	4477392
Idiosyncratic responses to phenothiazines.	1972-01-22	5058744
Increased sensitivity to neuroleptics in rats with lesions of the central nervous system.	1972	5065892
Iatrogenic epilepsy due to antidepressant drugs.	1969-10-11	5823053
Dystonic reaction to perphenazine.	1969-08-09	4184245
Perphenazine dystonia presenting as recurrent dislocation of the jaw.	1969-01	5765799
Phenothiazines and diabetes in hospitalized women.	1968-01	5634402
Oculogyric crises due to phenothiazines.	1967-07-22	6028472
Side-effects of phenothiazines.	1967-04-01	6021008
Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients.	1967-03-01	5336562
Phenothiazines in early labour.	1967-02-11	6017500
Drug-induced extrapyramidal symptoms: their incidence and treatment.	1967-01	6016862
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.	1967	4383787

Patents

Sample Use Guides

In Vivo Use Guide

Schizophrenia: In general, for adults, the dose is 0.6 to 4.8 g (6 to 48 mg as perphenazine) daily in several divided oral doses.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:39:05 GMT 2025` Edited by `admin` on `Mon Mar 31 23:39:05 GMT 2025`
Record UNII	YU5QUY724S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PERPHENAZINE FENDIZOATE

Common Name

English

PERPHENAZINE FENDIZOATE [JAN]

Preferred Name

English

Perphenazine fendizoate [WHO-DD]

Common Name

English

BENZOIC ACID, 2-((6-HYDROXY(1,1'-BIPHENYL)-3-YL)CARBONYL)-, COMPD. WITH 4-(3-(2-CHLORO-10H-PHENOTHIAZIN-10-YL)PROPYL)-1-PIPERAZINEETHANOL (1:1)

Systematic Name

English

BENZOIC ACID, O-((6-HYDROXY-3-BIPHENYLYL)CARBONYL)-, COMPD. WITH 4-(3-(2-CHLOROPHENOTHIAZIN-10-YL)PROPYL)-1-PIPERAZINEETHANOL

Systematic Name

English

Code System Code Type Description

EVMPD

SUB194304